Clinical trials have evidenced the participation of MR in blood pressure (BP) regulation by showing the beneficial effects of MR blockers in the treatment of high BP; including mild, moderate and resistant hypertension (Weinberger et al., 2002; Acelajado et al., 2019). This evidence concerns the gene NR3C2 and Hypertension resistant to conventional therapy.